Estradiol Free, Serum
Estradiol is the most potent endogenous estrogen. In the blood stream 1 to 3% is non-protein bound. This small percentage is the biologically active form; 40% is bound to sex-hormone binding globulin (SHBG) and the remainder is bound to albumin. The primary function of estradiol is to stimulate growth of the female sex organs and development of secondary sexual characteristics. Measurement in women generally reflects ovarian activity. Also, during fertility treatment estradiol monitoring is useful for assessing follicular growth. Elevated estradiol levels in females might result from primary or secondary ovarian hyperfunction. In nonpregnant females, most of the estradiol originates in the ovaries, with a smaller contribution from the adrenal glands. The placenta is an additional source of estradiol during pregnancy. It has been suggested that estrogens, including estradiol, is a very strong mood-orienting hormone in women. In fact, extreme fluctuations correlate well with depression. Decreased estradiol levels in females may result from either the lack of ovarian synthesis (primary ovarian hypofunction and/or menopause) or a lesion in the hypothalamus-pituitary axis (secondary ovarian hypofunction). Very high estradiol levels are found during the induction of ovulation for assisted reproductive therapy or in pregnancy. In males, 75% of estradiol is produced from testosterone and other androgens by an aromatase-catalyzed reaction in the peripheral tissues. The remaining 25% of estradiol in males is produced in the testes. Estradiol levels are normally low in males. Elevated estradiol levels in males may be due to increased aromatization of androgens, resulting in gynecomastia.
- Evaluation of hypothalamic and pituitary function
- Evaluation and assessment of ovarian function and follicular maturation
- Monitor puberty, primary and secondary amenorrhea, and menopause in females
- Monitor ovulation in patients being treated for infertility
- As an aid in diagnosis of gynecomastia in males
Increased in:
- Primary (Ovarian hyperstimulation syndrome) or secondary ovarian hyperfunction
Decreased in:
- Primary ovarian hypofunction and menopause or a lesion in the hypothalamus-pituitary axis (secondary ovarian hypofunction)
| Group | Category | pg/mL | pmol/L |
| Cord Blood | Cord Blood | 3000-29,000 | 11,010-106,430 |
| Prepubertal child | 30-60 days M | 10-32 | [37-117] |
| 30-60 days F | 5-50 | [18-184] | |
| 6 mo-10 yr | <15 | [55] | |
| Puberty (by Tanner stage) | 1 M | 3-15 | [11-55] |
| 1 F | 5-10 | [18-37] | |
| 2 M | 3-10 | [11-37] | |
| 2 F | 5-115 | [18-422] | |
| 3 M | 5-15 | [18-55] | |
| 3 F | 5-180 | [18-661] | |
| 4 M | 3-40 | [11-147] | |
| 4 F | 25-345 | [92-1266] | |
| 5 M | 15-45 | [55-165] | |
| 5 F | 25-410 | [92-1505] | |
| Adult | M | 10-50 | [37-184] |
| F early follicular phase | 20-150 | [73-551] | |
| F late follicular phase | 40-350 | [147-1285] | |
| F midcycle peak | 150-750 | [551-2753] | |
| F luteal phase | 30-450 | [110-1652] | |
| F postmenopausal | 20 | [73] |
Chemiluminescent immunoassay.
Serum (Red or SST).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Contraception. 2011 Nov 11. [PMID: 22078632]
- Ann Clin Biochem. 1988 Sep;25 ( Pt 5):466-83. [PMID: 3069043]
- Ann Clin Biochem. 2009 Nov;46(Pt 6):441-56. [PMID: 19841104]
- Speroff L, Glass RH, Kase NG (editors). Clinical gynecologic endocrinology and infertility. 4th ed. Baltimore:Williams and Wilkins (1989). p.91–119